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SUMMARY: Long-chain polyunsaturated fatty acids (LCPUFA) which are synthesized mainly in the liver 
have relevant functions in the organism. A diet high in fat (HFD) generates an increase in the levels of fat and 
induces oxidative stress (lipo-peroxidation) in the liver, along with a reduction in tissue n-3 and n-6 LCPUFA. 
Extra virgin olive oil (EVOO) is rich in anti-oxidants (polyphenols and tocopherols) which help to prevent 
the development of oxidative stress. This study evaluated the role of EVOO in preventing the induction of fat 
deposition and oxidative stress in the liver and in the depletion of LCPUFA in the liver, erythrocytes and brain 
generated by a HFD in C57BL/6J mice. Four experimental groups (n = 10/group) were fed a control diet (CD) 
or a HFD for 12 weeks and were respectively supplemented with EVOO (100 mg/day). The group fed HFD 
showed a significant increase (p < 0.05) in fat accumulation and oxidative stress in the liver, accompanied by a 
reduction in the levels of n-3 and n-6 LCPUFA in the liver, erythrocytes and brain. Supplementation with EVOO 
mitigated the increase in fat and oxidative stress produced by HFD in the liver, along with a  normalization 
of LCPUFA levels in the liver, erythrocytes and brain. It is proposed that EVOO supplementation protects 
against fat accumulation, and oxidative stress and normalizes n-3 and n-6 LCPUFA depletion induced in mice 
fed a HFD.
KEYWORDS: Extra virgin olive oil; High fat diet; Liver fat deposition; Oxidative stress; Tissue n-6 and n-3 LCPUFA 
depletion
RESUMEN: El aceite de oliva extra virgen reduce el estrés oxidativo hepático y la perdida tisular de ácidos 
 grasos poliinsaturados de cadena larga en tejidos de ratones alimentados con dieta alta en grasa saturada. Los 
ácidos  grasos poliinsaturados de cadena larga (AGPICL) sintetizados principalmente por el hígado, cumplen 
 funciones relevantes en el organismo. Una dieta alta en grasa (DAG) genera un incremento en los niveles de 
grasa y estrés oxidativo (lipoperoxidación) en hígado y una reducción en los niveles de AGPICL n-3 y n-6 en 
diferentes tejidos. El aceite de oliva extra virgen (AOEV) es rico en antioxidantes (polifenoles y tocoferoles) que 
ayudan a prevenir el desarrollo del estrés oxidativo. Este trabajo evaluó el rol del AOEV en la prevención del 
depósito de grasa, estrés oxidativo hepático y reducción de los AGPICL n-3 y n-6 en diferentes tejidos generado 
por una DAG en ratones C57BL/6J. Cuatro grupos experimentales (n=10/grupo) fueron alimentados (12 sema-
nas) con dieta control (DC) o DAG y suplementados con AOEV (100 mg/día). El grupo alimentado con DAG 
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presentó un incremento (p<0,05) en la acumulación de grasa y estrés oxidativo hepático, acompañado de una 
reducción en los niveles de AGPICL n-3 y n-6 en hígado, eritrocitos y cerebro. La suplementación con AOEV 
logró atenuar el incremento de la grasa y estrés oxidativo hepático, junto con una normalización en los niveles 
de AGPICL n-3 y n-6 en los tejidos estudiados. Se propone que la suplementación con AOEV puede atenuar la 
acumulación de grasa y el estrés oxidativo hepático, además de normalizar los niveles de AGPICL, en ratones 
alimentados con DAG.
PALABRAS CLAVE: Aceite de oliva extra virgen; Ácidos grasos poliinsaturados de cadena larga; Dieta alta en grasa; 
Estrés oxidativo; Hígado
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1. INTRODUCTION
The physiological and biochemical functions of 
n-3 and n-6 long-chain polyunsaturated fatty acids 
(LCPUFA) such as n-3 eicosapentaenoic acid (C20:5 
n-3, EPA) and docosahexaenoic acid (C22:6  n-3, 
DHA) and n-6 arachidonic acid (C20:4 n-6, AA) are 
solidly documented (Valenzuela, 2009; De Caterina, 
2011; Bazinet and Layé, 2014). EPA is associated 
with cardiovascular health, the anti-inflammatory 
response and the functioning of the immune system 
(Mozaffarian and Wu, 2012). DHA has a relevant 
role in the nervous and visual systems (Carlson, 
2009). AA is important for the immune system and 
brain development (Reddy et  al., 2015). EPA and 
DHA are synthesized from the precursor alpha-
linolenic acid (C18: 3 n-3, ALA) and AA from 
linoleic acid (C18:2 n-6, LA). EPA, DHA and AA 
are formed through elongation and de-saturation 
of the respective precursor carried out by elongase 
and desaturase enzymes (Valenzuela et  al., 2012; 
Valenzuela et  al., 2014). The activity of ∆-5 and 
∆-6 desaturase enzymes is mainly expressed in the 
liver and to a lesser extent in other tissues such as 
the brain and mammary glands (Nakamura and 
Nara, 2003; Nakamura and Nara, 2004). The con-
version of ALA to EPA and DHA is very low in 
mammals (rodents and humans) (Valenzuela et al., 
2014; Gibson et al., 2011) although it is estimated 
to be sufficient to obtain the physiological levels of 
EPA required in erythrocytes and the liver and of 
DHA in the brain and visual tissues (Gerster, 1998; 
Brenna et al., 2009). The formation of AA from LA 
is not limiting because of the high availability of 
LA in the typical western diet (Simopoulos, 2011). 
The activity of desaturases is positively regulated 
by insulin (Guillou et  al., 2010) and is very sensi-
tive to the cellular redox state (Nakamura and Nara, 
2004) modified by oxidative stress, which reduces 
the activity of desaturases (Valenzuela et al., 2015). 
Oxidative stress produced by reactive oxygen spe-
cies (free radicals) is associated to lipoperoxidation, 
which in turn is associated with the origin and/or 
progression of many diseases (Videla et al., 2006), 
being an important component of the deleterious 
effects of obesity (Videla et  al., 2004), and other 
non-transmissible chronic diseases (Li et al., 2004; 
Marseglia et  al., 2014). A diet high in saturated 
fat, particularly containing palmitic acid (C16:0), 
increases liver oxidative stress reducing n-3 and n-6 
LCPUFA (EPA, DHA and AA) in different tissues, 
such as erythrocytes, brain, heart, liver and adipose 
tissue (Valenzuela et al., 2015).
Extra virgin olive oil (EVOO) is characterized by 
health benefits, particularly in cardiovascular health 
(Visioli et al., 2005). Benefits have been associated to 
its content of oleic acid (Lim et al., 2013), but also 
to the content of non-triglyceride substances, such 
as tocopherols and polyphenols, which have anti-
oxidant and anti-inflammatory effects (Cicerale 
et al., 2012). This work shows that the induction of 
oxidative stress and the reduction of the tissue n-3 
and n-6 LCPUFA produced by a HFD in mice can 
be reversed by supplementing animals with EVOO. 
The benefit of antioxidants contained in EVOO 
against the development of oxidative stress induced 
by a HFD is discussed.
2. MATERIALS AND METHODS
2.1. Animals, diet and supplementation
Forty male C57BL/6J mice weighing 12–14 g 
(Central Biotherium, ICBM, Faculty of Medicine, 
Universidad de Chile) were randomly assigned into 
four experimental groups and allowed free access to 
the specially formulated control or high fat diets.
The composition of  the control diet (CD) 
(expressed as % total calories) was 10% fat, 20% 
protein, and 70% carbohydrate, with a caloric 
value of  3.85 kcal·g–1, free of  EPA and DHA, and 
 containing 0.7 g of  ALA·100g–1 of  diet. The com-
position of  the HFD was 60% fat, 20%  protein, 
and 20% carbohydrate, with a caloric value of 
5.24 kcal·g−1, free of  EPA and DHA and contain-
ing 0.7 g of  ALA·100 g–1 of  diet. Both diets were 
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obtained from Research Diet INC (Rodent Diet, 
Product data D12450B and D12492, USA). 
Table  1 shows the fatty acid composition of  the 
CD and HFD. The CD and HFD animals were 
separated into four groups (for CD 10+10 animals 
and for HFD 10+10 animals) and housed in sepa-
rated cages. One CD group received 100 mg·day–1 
of  EVOO and the other group an isovolumetric 
amount of  saline. One HFD group also received 
100 mg·day–1 of  EVOO and the other group iso-
volumetric saline. EVOO and saline were supplied 
through oral administration throughout a period 
of  12 weeks, thus comprising four experimental 
groups: (a) CD+saline, (b) CD+EVOO, (c) HDF+ 
saline, and (d) HFD+EVOO. Weekly controls 
of  body weight and diet intake were performed 
throughout the experimental period. At the end 
of  the experimental period (12th week), the ani-
mals were fasted overnight (6–8  h), anesthetized 
with ketamine and xylazine (150 and 10 mg·kg–1, 
respectively), and blood, liver and brain samples 
were extracted and frozen in liquid nitrogen for 
the assessment of  fat content, oxidative stress 
 parameters and fatty acid composition in the liver 
and for fatty acid composition in the erythrocytes 
and brain. The experimental animal protocols and 
animal procedures complied with the Guide for the 
Care and Use of  Laboratory Animals (National 
Academy of  Sciences, NIH Publication 6–23, 
revised 1985) and were approved by the Bioethics 
Committee for Research in Animals, Faculty of 
Medicine, University of  Chile (CBA#580 FMUCH 
and CBA#0630 FMUCH).
2.2.  Assays for total fat content and oxidative 
stress-related parameters in the liver
Once the animals were anesthetized livers were 
perfused in situ with a cold solution, containing 
150 mM KCl and 5 mM Tris (pH 7.4) to remove 
blood. The samples were taken for total fat, tria-
cylglycerols, reduced (GSH) and oxidized (GSSG) 
glutathione, protein carbonyls, F-2 isopros-
tanes and thiobarbituric acid reactant (TBARs) 
assessment. GSH and GSSG were assessed by 
an  enzymatic recycling method (Rahman et  al., 
2006). Protein carbonyls, F-2 isoprostanes, TBAR 
triacylglycerols and free fatty acids were measured 
using specific kits, according to the  manufacturer’s 
instructions (Cayman Chemical Company, Ann 
Arbor, MI, USA, for carbonyls, F-2 isopros-
tanes and TBARs and Wiener Lab, Argentina for 
triacylglycerols).
2.3. Fatty acid profile
The quantitative extraction and separation of 
total lipids from the liver, erythrocytes and brain 
was carried out according to the solvent mixture 
described by Bligh and Dyer (Bligh and Dyer, 
1959) added of butylated hydroxytoluene (BHT) as 
antioxidant. Erythrocyte and tissue samples were 
homogenized in ice-cold chloroform/methanol 
(2:1 v/v) containing 0.01% BHT in a homogenized 
Ultraturrax (Janke & Kunkel, Stufen, Germany). 
Total lipids from erythrocytes were extracted with 
chloroform/isopropanol (2:1 v/v). Phospholipids 
from the liver, erythrocytes and brain were separated 
from the total lipid extracts by thin layer chromatog-
raphy (TLC) on silica gel plates (aluminum sheets 
20x20 cm, silica gel 60 F-254; Merck), using the sol-
vent system hexane/diethyl ether/acetic acid (80:20:1 
v/v/v). After the development of plates and solvent 
evaporation lipid spots were visualized by exposing 
the plates to a Camag UV (250 nm) lamp designed 
for TLC. The solvent system allows for the separa-
tion of phospholipids, cholesterol, triacylglycerols 
and cholesterol esters according to their relative 
mobility. Phospholipid spots were removed from 
the plate with either diethyl ether or chloroform/
methanol (2:1 v/v), according to  Ruiz-Gutierrez 
et al. (1992).
2.4.  Preparation and gas chromatographic analysis 
of fatty acid methyl esters (FAMEs)
FAMEs from the liver, erythrocytes and brain 
phospholipids were prepared with boron trifluoride 
(12% methanolic solution) according to Morrison 
and Smith (1964), followed by a methanolic sodium 
hydroxide (0.5N) solution. Phospholipids for FAME 
synthesis were extracted from the silica gel spots with 
15 mL of chloroform/methanol/water (10:10:1) and 
Table 1. Fatty acid composition of the CD and the HFD
CD
Fatty acids
(g·100 g–1 diet)
HFD
Fatty acids
(g·100 g–1 diet)
C16:0 0.64 6.47
C18:0 0.32 3.67
Total SFA 1.01 10.7
C18:1 n-9 1.15 11.2
Total MUFA 1.19 11.9
18:2 n-6 (LA) 1.48 7.34
18:3 n-3 (ALA) 0.17 0.54
20:4 n-6 (AA) 0.004 0.070
20:5 n-3 (EPA) 0.000 0.000
22:6 n-3 (DHA) 0.000 0.000
Total PUFA 1.66 8.30
Fatty acid composition of the CD and the HFD. Values are 
expressed as g fatty acid per 100 g of diet. Saturated fatty acids 
(SFA) correspond to 10:0, 12:0, 14:0, 16:0, 18:0, 20:0 and 22:0. 
Monounsaturated fatty acids (MUFA) correspond to 14:1 n-7, 
16:1 n-7, 18:1 n-9 and 20:1 n-9. Polyunsaturated fatty acids 
(PUFA) correspond to 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:3 n-3, 20:4 
n-6, 20:5 n-3, 22:5 n-3, and 22:6 n-3.
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evaporated under a nitrogen stream. FAME  samples 
were cooled and extracted with 0.5 mL of hexane. The 
FAMEs were separated and quantified by gas-liquid 
chromatography in an Agilent  Hewlett-Packard 
equipment (model 7890A, CA, USA) using a capil-
lary column (Agilent HP-88, 100m×0.250 mm; I.D. 
0.25 µm) and a flame  ionization detector (FID). 
The injector temperature was set at 250 °C and the 
FID temperature at 300 °C. The oven temperature 
at injection was initially set at 140 °C and was pro-
grammed to increase to 220 °C at a rate of 5 °C per 
min. Hydrogen was used as the carrier gas (35 cm 
per second flow rate) in the column and the inlet 
split ratio was set at 20:1. The identification and 
quantification of FAMEs were achieved by compar-
ing the retention times and the peak area values (%) 
of the unknown samples with those of a commercial 
lipid standard (Nu-Chek Prep Inc). C23:0 was used 
as internal standard (Nu-Chek Prep  Inc, Elysian 
MN, USA) and a Hewlett-Packard Chemstation 
(Palo Alto, CA, USA) data system was used for the 
peak analysis.
2.5. Statistical analysis
A statistical analysis was performed with 
GraphPad Prism 6.0 software (GraphPad Prism 
Software, Inc. San Diego, USA). Values shown rep-
resent the mean±SEM for each  experimental group. 
Evaluations of normality in the data  distribution were 
performed using the Shapiro Wilk test. Assessment 
of the statistical significance of differences between 
mean values was made by the Newman-Keuls test. 
A p<0.05 was considered  significant. To analyze the 
association between  different variables, the Pearson 
correlation coefficient was used.
3. RESULTS
3.1. General and liver physiological parameters
Table 2 shows the general physiological param-
eters of initial and final body weight, liver weight, 
visceral adipose weight, and the liver parameters of 
total fat, triacylglycerols and free fatty acids obtained 
from mice fed the CD and HFD and supplemented 
with either saline or EVOO. It can be observed that 
HFD significantly modified the final body weight 
and the visceral adipose tissue weight of the animals 
(Table 2-A). The liver parameters also showed marked 
differences with respect to total fat, triacylglycerols 
and free fatty acids as a result of the HFD ingestion. 
EVOO supplementation (CD+EVOO) did not mod-
ify the general physiological parameters compared 
to the CD+saline group. The HFD significantly 
increased total fat (217%), triacylglycerols (229%), 
and free fatty acids (174%) when compared to the 
CD groups. HFD+EVOO substantially reduced total 
fat (26%), triacylglycerols (26%) and free fatty acids 
(16%) when compared to the HFD+saline group. 
However, values for the HFD+EVOO were far from 
those obtained for the CD+EVOO supplementation, 
showing that EVOO improved the modification of 
liver parameters induced by the HFD, but did not 
restore these parameters to the levels observed for the 
CD groups (Table 2-B).
3.2. Liver parameters of oxidative stress
The liver parameters of oxidative stress  evaluated 
from the mice of the CD and HFD groups are pre-
sented in Table 3. All parameters of oxidative stress, 
with the exception of GSSG, were modified by the 
Table 2. General and liver parameters of mice fed the control diet (CD) and the high fat 
diet (HFD) which received saline or EVOO supplementation
Groups
Control Diet (CD) High Fat Diet (HFD)
Saline (a) EVOO (b) Saline (c) EVOO (d)
A. General Parameters
Initial body weight (g) 14.5±2.2 14.5±2.5 14.6±1.9 14.4±2.6
Final body weight (g) 33.1±2.8c,d 34.2±2.9c,d 42.2±3.9a,b 43.4±3.5a,b
Liver weight (g) 0.98±0.09 0.97±0.7 1.21±0.2 1.17±0.3
Visceral adipose tissue (g) 1.08±0.4c,d 1.09±0.5c,d 3.94±0.5a,b 3.68±0.4a,b
B. Liver parameters
Total fat (mg·g–1 liver) 34.5±4.9c,d 30.1±2.9c,d 109.5±10.5a,b,d 80.3±8.6a,b,c
Triacylglycerols (mg·g–1 liver) 31.0±2.5c,d 26.4±2.2c,d 102±9.6a,b,d 75.6±7.8a,b,c
Free fatty acid (µM·g–1 liver) 276.8±23.5c,d, 255.6±27.8c,d, 756.4±50.2a,b,d 632.2±38.9a,b,c
Values represent means±SEM for 7–10 mice per experimental group. Significant differences 
between the groups are indicated by the letter identifying each group (p<0.05; one-way ANOVA 
and the Newman-Keuls´ test).
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HFD. GSH levels were significantly reduced in 
the HFD+saline compared to the CD groups but 
were partially restored by EVOO (HFD+EVOO). 
The other oxidative parameters (GSH/GSSG, pro-
tein carbonyls, F2-isoprostanes, TBARs, and the 
respective ratios with total GSH, were significantly 
increased by the HFD compared with the CD 
groups. EVOO (HFD+EVOO) reduced these values 
although they did not reach the levels observed for 
the CD+saline or CH+EVOO, with the exemption 
of the protein carbonyl values which were normal-
ized by EVOO supplementation. The results showed 
that oxidative stress induced by a HFD can be miti-
gated but not avoided by EVOO supplementation in 
the doses and time of supplementation applied in 
this experimental protocol.
3.3. Fatty acid composition of liver phospholipids
Table 4 shows the fatty acid composition of phos-
pholipids extracted from the liver of mice from the 
CD and HFD groups. The EVOO supplementation 
of the CD group did not produce any modifica-
tion in the fatty acid composition compared to the 
CD+saline. The HFD significantly reduced the most 
relevant n-6 (AA) and n-3 (ALA, EPA, DHA) fatty 
acids and other minor fatty acids as well (18:4 n-3; 20:3 
n-6; 20:4 n-3; 22:5 n-6 DPA n-6; 22:5 n-3 DPA n-3). 
The HFD also reduced total PUFA, total LCPUFA, 
total n-6 LCPUFA and total n-3 LCPUFA. The 
total SFA and n-6 LCPUFA/n-3 LCPUFA ratio 
were increased and only total MUFA was not modi-
fied by the HFD. These results show that the HFD 
produced a substantial modification in the fatty acid 
composition of liver phospholipids. However, the 
HFD+EVOO showed a significant difference com-
pared to the HFD+saline group. Supplementation of 
the HFD group with EVOO avoided the reduction in 
ALA, AA, EPA and DHA, and of the other minor 
fatty acids, showing values similar to those obtained 
for the CD groups. The same behavior was observed 
for total PUFA, total LCPUFA, total n-6 and n-3 
LCPUFA and for the n-6 LCPUFA/n3 LCPUFA 
ratio. Interestingly, some fatty acids, such as 16:0, LA 
and 18:3 n-6, and total MUFA, were not modified by 
the supplementation of the HFD group with EVOO 
compared to the CD groups.
3.4.  Fatty acid composition of erythrocyte 
phospholipids
Table 5 shows the fatty acid composition of 
phospholipids extracted from erythrocytes from the 
mice of  the CD and HFD groups. The CD+EVOO 
group did not show differences, when compared to 
the CD+saline, for 16:0, LA, ALA, AA, 22:5, n-6 
DPA n-6, DHA, total PUFA, total LCPUFA, total 
n-6 LCPUFA and the n-6 LCPUFA/n-3 LCPUFA 
ratio. However the CD+EVOO produced a reduc-
tion in EPA and 22:5 n-3 DPA n-3 and increased 
18:1 n-9 and total MUFA. HFD+saline produced 
the greatest reduction in EPA and 22:5 n-3 DPA 
n-3 were observed for the CD+EVOO, which 
also reduced DHA, total MUFA, total PUFA, 
total LCPUFA and total n-3 LCPUFA, increas-
ing by 16:0, the total SFA and n-6 LCPUFA/n-3 
LCPUFA ratio. EVOO supplementation to the 
HFD group restored the values for EPA, 22:5 n-6 
DPA n-6; 22:5 n-3 DPA n-3 and DHA to levels 
close to the CD+saline and the CD+EVOO. The 
effect of  EVOO supplementation on mice fed the 
HFD in erythrocyte phospholipid fatty acids was 
not as relevant as was observed for liver phospho-
lipid fatty acids.
Table 3. Parameters of liver oxidative stress of mice fed the control diet (CD) 
and the high fat diet (HFD) and receiving EVOO supplementation
Groups
Control Diet (CD) High Fat Diet (HFD)
Liver oxidative stress parameters Saline (a) EVOO (b) Saline (c) EVOO (d)
GSH (μmol·g–1 liver) 5.95±0.5c,d 6.8±0.5c,d 3.76±0.3a,b,d 4.80±0.3a,b,c
GSSG (μmol·g–1 liver) 0.48±0.04 0.43±0.03 0.45±0.02 0.48±0.03
Total GSH equivalents (μmol·g–1 liver) 6.44±0.7c,d 7.24±0.8c,d 4.21±0.4a,b,d 5.28±0.3a,b,c
GSH/GSSG ratio  12.4±1.8c,d 15.8±2.0c,d 8.40±0.8a,b,d 10.1±0.6a,b,c
Protein carbonyls (nmol·mg–1 protein) 2.3±0.4c 2.08±0.3c 4.12±0.6a,b,d 2.78±0.2c
F2-isoprostanes (pg·mg–1 protein) 9.08±1.0c,d 8.94±1.1c,d 16.5±1.9a,b,d 12.8±1.3a,b,c
TBARs (nmol·mg–1 protein)  0.08±0.02c,d 0.06±0.01c,d 0.15±0.01a,b,d 0.10±0.02a,b,c
Protein carbonyl/total GSH ratio (arbitrary units) 0.38±0.01b,c,d 0.31±0.02a,c,d 1.10±0.3a,b,d 0.58±0.02a,b,c
F2-isoprostane/total GSH ratio (arbitrary units) 1.52±0.04b,c,d 1.31±0.03a,b,c 4.39±0.5a,b,d 2.67±0.3a,b,c
TBAR/total GSH ratio (arbitrary units) 0.01±0.001c,d 0.01±0.001c,d 0.04±0.01a,b,d 0.02±0.005a,b,c
Values represent means±SEM for 7–10 mice per experimental group. Significant differences between the groups are indicated by the 
letter identifying each group (p<0.05; one-way ANOVA and the Newman-Keuls’ test). Total GSH equivalents=GSH+2GSSG.
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3.5. Fatty acid composition of brain phospholipids
Table 6 shows the fatty acid composition of 
phospholipids extracted from the brain of mice 
fed the CD and HFD. EVOO supplementation to 
the CD group did not produce any modification in 
the fatty acid composition of the brain showing the 
high reluctance of this tissue to this dietary modi-
fication. However, the HFD produced a  general 
deterioration in the n-6 and n-3 fatty acid contents 
of brain phospholipids because ALA, AA, 22:5 n-6 
DPA n-6, 22:5 n-3 DPA n-3, DHA, total PUFA, 
total LCPUFA, total n-6 LCPUFA, and total n-3 
LCPUFA were reduced to lower levels than observed 
in the CD groups (saline and EVOO). The HFD also 
raised 16:0 and SFA, showing the potential danger-
ous effect of this diet to this highly sensitive tissue. 
EVOO supplementation to the HFD group restored 
the levels of the main n-6 and n-3 fatty acids to 
levels similar to the CD groups with the exception 
of 22:5 n-6 DPA n-6 and 22:5 n-3 DPA n-3 fatty 
acids. This protective action was also observed for 
total n-6 LCPUFA, total n-3 LCPUFA and the n-6 
LCPUFA/n-3 LCPUFA ratio.
3.6.  Liver product/precursor ratio for n-3 and 
n-6 LCPUFA
Figure 1 shows the liver product/precursor ratio 
for n-3 LCPUFA ((EPA+DHA)/ALA) (Figure 1-A) 
and n-6 LCPUFA (AA/LA) (Figure 1-B) for the dif-
ferent experimental groups. It can be observed that 
both ratios were strongly modified by the HFD and 
that EVOO supplementation to this group restored 
the ratio to similar values of the ratios observed in 
the CD groups.
Table 4. Fatty acid composition of liver phospholipids obtained from mice fed the control diet (CD) 
and the high fat diet (HFD) and receiving EVOO supplementation
Fatty acid composition (g·100 g–1 FAME)
Groups
Control Diet (CD) High Fat Diet (HFD)
Fatty acid Saline (a) EVOO (b) Saline (c) EVOO (d)
16:0 36.8±2.3c 35.7±2.1c 45.2±3.4a,b,d 35.9±2.2c
18:1 n-9 22.9±1.9b,d 29.7±2.3a,c 24.6±2.8b,d 29.1±2.0a,c
18:2 n-6 (LA) 13.2±1.3 12.4±1.2 11.1±1.3 14.6±1.0
18:3 n-6 1.05±0.1 0.92±0.04 0.88±0.05 1.03±0.02
18:3 n-3 (ALA) 1.14±0.2c 1.12±0.1c 0.89±0.1a,b,d 1.09±0.1c
18:4 n-3 0.25±0.06c 0.24±0.03 c 0.13±0.01a,b,d 0.23±0.05c
20:3 n-6 0.20±0.03c 0.21±0.04 c 0.08±0.04a,b,d 0.18±0.02c
20:4 n-6 (AA) 11.8±1.0c 10.1±0.8c 7.18±0.7a,b,d 10.9±0.8c
20:4 n-3 0.15±0.0c 0.14±0.02c 0.06±0.02a,b,d 0.12±0.02c
20:5 n-3 (EPA) 1.06±0.2c 1.01±0.1c 0.40±0.02a,b,d 0.95±0.1c
22:5 n-6 (DPAn-6) 0.08±0.01c 0.07±0.02c 0.03±0.01a,b,d 0.07±0.03c
22:5 n-6 (DPAn-3) 0.10±0.01c 0.09±0.02c 0.05±0.01a,b,d 0.08±0.02c
22:6 n-3 (DHA) 4.19±0.5c 3.89±0.3c 2.19±0.2a,b,d 3.85±0.2c
Total SFA 38.3±3.4c 33.9±2.3c 47.2±3.6a,b,d 37.8±2.7c
Total MUFA 26.9±2.7 32.2±2.6 29.5±2.1 30.8±2.5
Total PUFA 34.8±3.2c 33.9±2.1c 23.3±1.7a,b,d 31.4±1.8c
Total LCPUFA 18.2±0.9b,c 15.9±0.5a,c 10.2±0.8a,b,d 16.4±1.1c
Total n-6 LCPUFA 12.6±0.8b,c 10.7±0.6a,c 7.40±0.1a,b,d 11.2±0.8c
Total n-3 LCPUFA 5.60±0.3c 5.21±0.2c 2.80±0.05a,b,d 5.20±0.3c
n-6 LCPUFA/n-3 LCPUFA ratio 2.25±0.1c 2.10±0.1c 2.60±0.2a,b,d 2.18±0.1c
Values are expressed as g fatty acid per 100 g FAME and represent the mean ± SEM for n=8 mice per experimental group. Significant 
differences between the groups are indicated by the letter identifying each group (p<0.05; one-way ANOVA and the Newman-Keuls’ 
test). Saturated fatty acids (SFA) correspond to 14:0, 16:0 and 18:0. Monounsaturated fatty acids (MUFA) correspond to 14:1 n-7, 
16:1 n-7 and 18:1 n-9. Polyunsaturated fatty acids (PUFA) correspond to 18:2 n-6, 18:3 n-3, 20:4 n-6, 20:5 n-3, 22:5 n-3, and 22:6 n-3; 
n-6 long-chain polyunsaturated fatty acids (LCPUFA) are 20:4 n-6; n-3 LCPUFA are 20:5 n-3, 22:5 n-3, and 22:6 n-3; n-6/n-3 ratio: 
20:4 n-6/ (20:5 n-3 + 22:5 n-3 + 22:6 n-3).
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Table 5. Fatty acid composition of erythrocyte phospholipids from mice fed the control diet (CD) and the high fat 
diet (HFD) and receiving EVOO supplementation
Fatty acid composition (g·100 g–1 FAME)
Groups
Control Diet (CD) High Fat Diet (HFD)
Fatty acid Saline (a) EVOO (b) Saline (c) EVOO (d)
16:0 22.4±1.9c,d 21.1±1.6c,d 42.1±1.9a,b,d 38.5±2.6a,c
18:1 n-9 21.8±1.5b,d 26.4±1.8a,c 19.4±1.6b,d 25.6±1.6a,c
18:2 n-6 (LA) 12.4±0.8 11.0±0.7 10.3±0.8 10.9±0.8
18:3 n-3 (ALA) 1.16±0.2 1.10±0.1 0.97±0.06 0.99±0.05
20:4 n-6 (AA) 14.1±0.8 12.7±0.6 13.7±0.6 13.2±0.5
20:5 n-3 (EPA) 2.01±0.3b,c,d 1.62±0.04a,c 0.81±0.03a,b,d 1.57±0.05a,c
22:5 n-6 (DPAn-6) 0.14±0.02c 0.10±0.02 0.06±0.01a,b,d 0.11±0.02c
22:5 n-3 (DPAn-3) 0.80±0.05b,c,d 0.60±0.04a,c 0.04±0.01a,b,d 0.60±0.03a,c
22:6 n-3 (DHA) 4.03±0.3c,d 3.80±0.2c 2.15±0.03a,b,d 3.60±0.1a,c
Total SFA 39.3±3.3c 37.3±3.0c 47.2±2.6a,b,d 41.8±2.4c
Total MUFA 25.7±1.7b 30.1±2.1a,c 23.4±1.8b,d 27.8±1.9c
Total PUFA 35.0±3.9c 32.6±2.1 29.4±2.0a 30.4±2.9
Total LCPUFA 21.1±1.8c 19.0±1.2 16.9±0.9a 19.1±1.6
Total n-6 LCPUFA 14.3±0.8 12.9±0.4 13.8±0.8 13.3±
Total n-3 LCPUFA 6.80±0.3b,c,d 6.10±0.2a,c 3.10±0.04a,b,d 5.70±0.2a,c
n-6 LCPUFA/n-3 LCPUFA ratio 2.10±0.4c 2.11±0.4c 4.45±0.02a,b,d 2.33±0.3c
Values are expressed as g fatty acid per 100 g FAME and represent the mean ± SEM for n=8 mice per experimental group. 
Significant differences between the groups are indicated by the letter identifying each group (p<0.05; one-way ANOVA and 
the Newman-Keuls’ test). Identification of saturated and unsaturated fatty acids and their relationships are shown in table 4.
Table 6. Fatty acid composition of brain phospholipids from mice fed the control diet (CD) and the high fat diet 
(HFD) and receiving EVOO supplementation
Fatty acid composition (g·100 g–1 FAME)
Groups
Control Diet (CD) High Fat Diet (HFD)
Fatty acid Saline (a) EVOO (b) Saline (c) EVOO (d)
16:0 38.6±2.4c,d 37.5±2.1c,d 46.2±3.4a,b 43.2±2.6a,b
18:1 n-9 21.7±1.9 23.4±2.1 21.4±1.6 24.2±2.0
18:2 n-6 (LA) 4.01±0.3 3.91±0.2 3.88±0.2 3.94±0.3
18:3 n-3 (ALA) 1.20±0.2c 1.16±0.3c 0.63±0.1a,b,d 1.04±0.2c
20:4 n-6 (AA) 16.8±1.3c 16.4±1.1c 11.9±0.6a,b,d 15.1±0.8c
20:5 n-3 (EPA) 0.52±0.03c 0.49±0.04c 0.23±0.01a,b,d 0.49±0.02c
22:5 n-6 (DPAn-6) 0.22±0.02c,d 0.23±0.02c,d 0.84±0.04a,b,d 0.42±0.01a,b,c
22:5 n-6 (DPAn-3) 0.50±0.04c,d 0.48±0.05c,d 0.25±0.06a,b,d 0.38±0.02a,b,c
22:6 n-3 (DHA) 10.2±0.9c 10.0±0.7c 7.19±0.6a,b,d 9.81±0.5c
Total SFA 41.2±3.2c 40.8±2.8c 50.6±3.6a,b,d 45.2±3.7c
Total MUFA 24.3±1.7 25.3±1.6 22.6±2.0 26.1±2.1
Total PUFA 34.5±2.4c,d 33.9±2.2c,d 26.8±1.7a,b 28.7±1.9a,b
Total LCPUFA 28.3±2.2c 27.9±1.9c 20.5±1.8a,b,d 26.3±1.6c
Total n-6 LCPUFA 17.1±1.1c 16.8±1.0c 12.8±1.1a,b,d 15.6±1.3
Total n-3 LCPUFA 11.2±0.6c 11.1±0.8c 7.70±0.1a,b,d 10.7±0.8c
n-6 LCPUFA/n-3 LCPUFA ratio 1.53±0.05c 1.51±0.06c 1.66±0.05a,b,d 1.46±0.03c
Values are expressed as g fatty acid per 100 g FAME and represent the mean ± SEM for n=8 mice per experimental group. 
Significant differences between the groups are indicated by the letter identifying each group (p<0.05; one-way ANOVA and 
the Newman-Keuls’ test). Identification of saturated and unsaturated fatty acids and their relationships are shown in table 4.
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3.7.  Correlation of liver oxidative stress parameters 
(lipoperoxidation) with individual n-6 and n-3 
LCPUFA
Figure 2 shows the correlation of each parameter 
of liver oxidative stress with the tissue levels of each 
n-6 and n-3 LCPUFA. It can be observed (Figure 2 
A to E) that low levels of individual n-6 and n-3 
LCPUFA and of total n-6 and n-3 LCPUFA show 
a high correlation with high levels of all oxidative 
stress parameters evaluated in liver tissue.
4. DISCUSSION
Feeding animals a HFD produced a significant 
increase in the final body weight and in the weight 
of visceral adipose tissue. In addition, hepatic 
parameters such as total fat, triacylglycerides and 
free fatty acids were also increased (Table 2 A-B). 
These effects reflect a pro-lipogenic (greater activity 
of fatty acid synthesis) and pro-steatotic (greater fat 
deposition) actions of the HFD that are linked to 
the increase in the liver oxidative stress parameters 
assayed (Table  3). In this regard, an excess of fat 
in the liver, and especially free fatty acids, creates a 
phenomenon of intracellular toxicity (lipotoxicity) 
that significantly alters cellular metabolism (Pardo 
et  al., 2015). The HFD also produced an increase 
in reticular stress in mice which can cause altera-
tions in the folding of hepatic proteins (Lu et  al., 
2015), potentially  modifying many enzymatic func-
tions (Li  et  al., 2014). Liver fat accumulation and 
 oxidative stress would be linked to the reduction 
of the n-3 and n-6 LCPUFA observed in the liver, 
erythrocytes and the brain (Tables 4 to 6), effects 
that may be directly linked to the increase in sys-
temic and hepatic oxidative stress parameters previ-
ously observed in the mice fed the HFD (Valenzuela 
et  al., 2015). It has been described that the accu-
mulation of fat in the liver (from over load of satu-
rated fat and refined carbohydrates of nutritional 
origin) generates a decrease in the activity of the 
nuclear peroxisome proliferator-activated recep-
tor transcription factor alpha (PPAR-α) as a direct 
consequence of the reduction in tissue levels of n-3 
LCPUFA and, in addition, an increase in the activ-
ity of the sterol regulatory element binding protein 
transcription factor - 1 c (SREBP-1 c) (Pawlak et al., 
2015), thus promoting a pro-lipogenic state, particu-
larly expressed as greater synthesis of 16:0, as shown 
in tables 4, 5 and 6, and a reduction in the oxidation 
of fatty acids as a source of energy (Cheng et al., 
2015). The fall of the liver levels of n-3 LCPUFA, 
especially EPA and DHA, also severely affects the 
development of pro-oxidative and pro-inflamma-
tory states (Valenzuela et  al., 2012) as a result of 
the reduction in the erythroid nuclear transcription-
related factor 2 (Nrf-2) (Kwan et  al., 2015) and a 
strengthening of a hepatic pro-inflammatory state 
because an increase in the activity of the nuclear 
transcription factor kappa-B (NF-κB) (Videla et al., 
2009). Regarding these effects it has been shown in 
HFD-fed mice that dietary supplementation with 
n-3 LCPUFA for 12 weeks can prevent the accumu-
lation of fat in the liver, and that the activation of 
PPAR-α transcription factor and the inactivation of 
the hepatic NF-κB transcription factor are relevant 
participants in this effect (Tapia et al., 2014).
EVOO supplementation during the time and the 
dose provided in our experimental protocol partially 
protects liver oxidative stress and the accumulation 
of hepatic fat induced by a HFD. EVOO contains a 
significant amount of antioxidants (tocopherols and 
polyphenols) (Cicerale et al., 2012) that may protect 
liver tissue from oxidative stress. Within the poly-
phenols of EVOO, hydroxytyrosol has been shown 
to have the ability to activate the Nrf2, a transcrip-
tion factor that stimulates the expression of antioxi-
dant enzymes, such as heme oxigenase-1, glutamate 
cysteine ligase, glutathione peroxidase, glutathione 
reductase and catalase (Zhu et al., 2010; Zrelli et al., 
2011), thus promoting a better antioxidant response 
FIGURE 1. Liver product/precursor ratio for n-3 and n-6 
LCPUFA from mice fed the control diet (CD) and the high fat 
diet (HFD) and receiving EVOO supplementation.
Significant differences between groups are indicated by the 
letter identifying each group (p<0.05; one-way ANOVA and the 
Newman-Keuls’test).
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at the intracellular level, which may protects against 
the oxidation of proteins (Table 3) and preserve the 
activity of redox-sensitive enzymes, such as desatu-
rases (Nakamura and Nara, 2004; Valenzuela et al., 
2015). Another interesting aspect of EVOO is its 
high content of 18:1 n-9, which, although it is more 
stable to lipo-oxidation compared to PUFAs, can be 
also oxidized in low quantity, which could generate 
a  protective response as an increase in cellular anti-
oxidant defenses (Haeiwa et al., 2014). The decrease 
in n-3 and n-6 LCPUFA observed in the three tissues 
studied may be a consequence of the oxidative stress 
induced by the HFD, which has an impact on the 
reduction in the activity of  desaturase enzymes (Δ-5 
and Δ-6 desaturases), as previously shown (Valenzuela 
et  al., 2015). In this way, the antioxidant compo-
nents of EVOO would protect the effect of a HFD 
on the activity of desaturase enzymes in the liver, on 
the tissue levels of n-3 and n-6 LCPUFA, on lipo- 
peroxidation as  measured through F2-isoprostanes 
and TBARS (Table 3), and on the negative correla-
tion of lipoperoxidation parameters and liver levels of 
FIGURE 2. Correlation between liver oxidative stress (lipoperoxidation) and n-3 and n-6 LCPUFA from mice fed the control diet 
(CD) and the high fat diet (HFD) and receiving EVOO supplementation.
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n-3 and n-6 LCPUFA (Figure 2 A to E). The protec-
tive effect of EVOO on n-3 and n-6 LCPUFA in the 
liver may explain the higher levels of these fatty acids 
measured in this tissue after EVOO supplementation 
(Table 4 and Figure 2), thus allowing for a reduc-
tion in the increase in fat in the liver, particularly of 
saturated fatty acids such as palmitic acid (C16:0), 
(Tables 4–5). It is interesting to note that the HFD 
significantly reduced the levels of AA and DHA in 
the brain, which could be the result of a lower liver 
synthesis and/or transport of these fatty acids to the 
brain and/or to a lower brain activity of AA and 
DHA synthesis from their precursors (Valenzuela 
et al., 2015; Lin et al., 2015). Also palmitic acid, the 
main fatty acid in the HFD (table 1), induces cellu-
lar lipotoxicity, thus altering lipid metabolism in liver 
cells (Nissar et al., 2015). In this regard, this is a fact 
of no minor importance, particularly if it is consid-
ered that the physiological conversion of AA and 
DHA from their 18 carbon atom precursors (LA and 
ALA) is essential to ensure a proper functioning of 
the brain (Domenichiello et al., 2014; Domenichiello 
et al., 2015). In the case of DHA its reduction in mem-
brane phospholipids might reflect the cytoprotective 
action of neuroprotectins generated by the release of 
this fatty acid from phospholipids and subsequent 
enzymatic metabolism to be transformed into doco-
sanoids with neuroprotective actions, such as neuro-
protectin D-1 (Orr et al., 2013). The restoring of AA 
and DHA levels observed in the HFD+EVOO group 
would reflect a normalization of these fatty acids in 
the brain, which in turn may result in improved neural 
functioning. However this is a statement that requires 
major studies. The reduction in the n-6 LCPUFA/n-3 
LCPUFA ratio by EVOO in the HFD-fed mice 
(Tables 4 to 6) is another noteworthy aspect because 
the increase in this ratio favors the development of 
cardiovascular disease, non-alcoholic fatty liver dis-
ease and other chronic diseases (Simopoulos, 2008; 
Valenzuela and Videla, 2011). EVOO consumption 
may be highly advisable for the protection or preven-
tion of these disabling diseases. Results of the pres-
ent research open an interesting challenge to study the 
protective effect of EVOO in HFD at the molecular 
level, aiming to better understand the beneficial effect 
of this noble natural product in the protection of the 
accumulation of fat and the development of oxidative 
stress in the liver and of the depletion of n-6 and n-3 
LCPUFA levels in this and other tissues, such as the 
brain, induced by a HFD.
5. CONCLUSIONS
Dietary supplementation of mice fed a HFD with 
EVOO allowed the liver to: i) reduce fat deposition; 
ii) reduce oxidative stress and; iii) normalize the loss 
of n-3 and n-6 LCPUFA. The protective effect of 
EVOO on n-3 and n-6 LCPUFA was also observed 
in phospholipids obtained from erythrocytes and 
the brain. The results demonstrate the protective 
action of EVOO against the physio-pathological 
effects of a HFD. However, it is necessary to extend 
these studies on the effect of HFD and the protec-
tive action of EVOO at a molecular level, evaluat-
ing the effects of the dietary intervention and of the 
supplementation with EVOO on the activity and 
expression of desaturase enzymes, the changes in 
the expression of genes involved in the maintenance 
of a cellular redox state and the protection against 
oxidative stress, and in the metabolism of fatty acids. 
We are currently working on these issues.
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